The Hyperlipidemia Drugs Market is expected to register a CAGR of 2.3% during the forecast period. The hyperlipidemia drug market is growing at a good rate attributing to increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia. Moreover, upcoming patent expiration lead to genericization in the market, mostly in statins and cholesterol absorption inhibitors which further fuel the market to certain extent. Several product launches are also anticipated to drive the hyperlipidemia drugs market. For instance, Recent launch of Repatha (2016) and Praluent (2017) is likely to change the current therapeutic scenario due to their improved efficacy and safety profile.
Key Market Trends
Statin Hyperlipidemia Drugs Segment is Expected to witness healthy growth in the Hyperlipidemia Drugs Market
Statins is expected to witness a healthy CAGR owing to surge in the incidence of cardiovacular disorders. Statins are the first line therapy which reduces the risk associated with heartattacks which also contributes to the growth of the market. Furthermore Benefits such as improved endothelial function, enhance the stability of atherosclerotic plaques , reduce the amount of inflammation and damage done to cells due to oxidative stress is also resposible for preferring of statins and drive the market. Moreover, PCSK9 inhibiotrs is also expected to grow in forcasted period attributed to drastic reduction of LDL levels in the blood.
Europe is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Europe is expected to hold a major market share in the global Hyperlipidemia Drugs market due to increasing prevalence of hypercholesteremia, increasing healthcare expenditure and presence of well-established healthcare infrastructure. Moreover, surge in obese population in this region leading to adopt hyperlipidemia drugs for diagnostic purpose is also anticipated to contribute to promote market growth.
Competitive Landscape
The Hyperlipidemia Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Dr. Reddy's Laboratories, Mylan, Amgen, Sanofi, AstraZeneca, Merck & Co., Inc, and DAIICHI SANKYO COMPANY, LIMITED.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Mylan NV
- Amgen
- Sanofi
- DAIICHI SANKYO COMPANY, LIMITED
- AstraZeneca
- ESPERION Therapeutics, Inc
- Merck & Co., Inc
- Pfizer Inc.
Methodology
LOADING...
